Orchid Pharma

Which are the latest news on Orchid Pharma?

Why is Orchid Pharma Ltd falling/rising?

As of 24-Jun, Orchid Pharma Ltd's stock price is rising at Rs 991.00, with a recent gain of 3.34% over two days and a 42.12% increase over the past year. Despite concerns about long-term fundamentals, the stock shows strong recent performance and high institutional confidence.

As of 24-Jun, Orchid Pharma Ltd's stock price is rising, currently at Rs 991.00, with a change of 2.8 (0.28%) upward. The stock has shown a positive performance recently, gaining 3.34% over the last two days and outperforming its sector by 0.25% today. Additionally, the stock has generated impressive returns over the past year, with a 42.12% increase, and has outperformed the BSE500 index over the last three years, one year, and three months.<BR><BR>Despite a recent decline of 4.16% over the past week, the stock's long-term performance remains strong, with a 39.97% increase over the last month and a 30.54% rise year-to-date. The high institutional holdings at 21.12% indicate confidence from larger investors, as their stake has increased by 0.56% over the previous quarter. <BR><BR>However, it is important to note that there are concerns regarding the company's long-term fundamental strength, as indicated by a low average Return on Equity (ROE) of 5.10% and a significant decline in profits over the past year. Despite these issues, the recent price movements and institutional confidence suggest that the stock is currently experiencing upward momentum.

Should I buy, sell or hold Orchid Pharma Ltd?

How big is Orchid Pharma?

As of 10th June, Orchid Pharma Ltd has a market capitalization of 4,324.00 Cr, with recent net sales of 811.33 Cr and a net profit of 20.36 Cr. The latest balance sheet shows shareholder's funds of 1,267.29 Cr and total assets of 1,687.91 Cr.

As of 10th June, Orchid Pharma Ltd has a market capitalization of 4,324.00 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, Orchid Pharma reported Net Sales of 811.33 Cr and a Net Profit of 20.36 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 1,267.29 Cr and Total Assets of 1,687.91 Cr.

Who are in the management team of Orchid Pharma?

The management team of Orchid Pharma includes Ram Gopal Agarwal (Chairman), Manish Dhanuka (Managing Director), Mridul Dhanuka (Whole-time Director), and Marina Peter (Company Secretary). The board also features Independent Directors Tanu Singla, Dharam Vir, Mudit Tandon, and Manoj Goyal.

The management team of Orchid Pharma includes the following key members:<BR><BR>1. **Ram Gopal Agarwal** - Chairman (Non-Executive)<BR>2. **Manish Dhanuka** - Managing Director<BR>3. **Mridul Dhanuka** - Whole-time Director<BR>4. **Marina Peter** - Company Secretary & Compliance Officer<BR><BR>Additionally, there are several Independent Directors on the board:<BR><BR>- **Tanu Singla**<BR>- **Dharam Vir**<BR>- **Mudit Tandon**<BR>- **Manoj Goyal**<BR><BR>This team plays a crucial role in overseeing the company's operations and strategic direction. If you need more specific details about any of the members or their roles, feel free to ask!

Who are the peers of the Orchid Pharma?

Orchid Pharma's peers include Aarti Pharma, Senores Pharma, Innova Captab, and others, with varying management and growth risks. Senores Pharma leads in 1-year returns at 117.67%, while Orchid Pharma has a 1-year return of 16.38% and below-average growth.

Peers: The peers of Orchid Pharma are Aarti Pharma, Senores Pharma., Innova Captab, Bliss GVS Pharma, Guj. Themis Bio., Advanced Enzyme, IOL Chemicals, Gufic BioScience, Panacea Biotec, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Senores Pharma. and Guj. Themis Bio., while Good management risk is found at Innova Captab. Average management risk is present at Aarti Pharma, Bliss GVS Pharma, Advanced Enzyme, IOL Chemicals, and Gufic BioScience, and the rest. Below Average management risk is noted at Orchid Pharma and Panacea Biotec. Growth is Excellent at Senores Pharma., while Average growth is seen at Senores Pharma., Advanced Enzyme, IOL Chemicals, and the rest. Below Average growth is noted at Aarti Pharma, Innova Captab, Bliss GVS Pharma, Guj. Themis Bio., Gufic BioScience, Orchid Pharma, Panacea Biotec, and Zota Health Care.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Senores Pharma. at 117.67%, while Orchid Pharma's 1-year return is 16.38%, which is lower than that of Senores Pharma. The peer with the lowest 1-year return is Aarti Pharma at -31.47%. Additionally, the six-month return is negative for Orchid Pharma, Guj. Themis Bio., Advanced Enzyme, and Zota Health Care.

What does Orchid Pharma do?

Orchid Pharma Ltd is a leading Indian pharmaceutical company specializing in the Pharmaceuticals & Biotechnology sector, with a market cap of INR 4,324 Cr. As of March 2026, it reported net sales of 238 Cr and a net profit of 24 Cr.

Overview:<BR>Orchid Pharma Ltd is a leading pharmaceutical company in India, operating in the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap.<BR><BR>History:<BR>Orchid Pharma was incorporated in the year not specified in the source data. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 238 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 24 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 4,324 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 160.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.22 <BR>Return on Equity: 2.09% <BR>Price to Book: 3.37 <BR><BR>Contact Details:<BR>Address: Orchid Towers Nungambakkam, 313 Valluvar Kottam High Road Chennai Tamil Nadu : 600034 <BR>Phone: 91-44-28211000/28230000 <BR>Email: corporate@orchidpharma.com <BR>Website: http://www.orchidpharma.com

Are Orchid Pharma Ltd latest results good or bad?

Orchid Pharma Ltd's latest Q4 FY26 results show a significant recovery in profitability, with a net profit of ₹23.78 crores and improved operating margins. However, the stock has underperformed over the past year, and high valuation metrics raise concerns about sustainability, suggesting investors should be cautious.

Orchid Pharma Ltd's latest results for Q4 FY26 indicate a significant recovery in profitability, marking a positive turnaround after two consecutive quarters of losses. The consolidated net profit reached ₹23.78 crores, which is a remarkable increase of 288.58% compared to the previous quarter. This also represents a 6.68% increase year-on-year. Additionally, net sales hit an all-time quarterly high of ₹237.61 crores, reflecting a sequential growth of 14.64%, although year-on-year growth was minimal at 0.05%.<BR><BR>The operating margin improved notably to 11.31%, up from just 0.76% in the previous quarter, indicating better operational efficiency. The profit after tax (PAT) margin also recovered to 9.59% from a negative margin of -5.86% in Q3 FY26.<BR><BR>However, despite these positive results, the company faces challenges. The stock has underperformed over the past year, declining 1.88%, and is down 29.08% over the last two years. The high valuation metrics, with a trailing P/E ratio of 140.23 times compared to the sector average of 34 times, raise concerns about sustainability and investor expectations.<BR><BR>In summary, while the latest quarter's results show strong recovery and improved profitability, the underlying issues related to valuation and past performance suggest that investors should approach with caution.

When is the next results date for Orchid Pharma Ltd?

The next results date for Orchid Pharma Ltd is 25 May 2026.

The next results date for Orchid Pharma Ltd is scheduled for 25 May 2026.

Is Orchid Pharma technically bullish or bearish?

As of December 4, 2025, the trend has shifted to mildly bullish, supported by daily moving averages and a bullish RSI on the monthly chart, though mixed signals from the MACD and Bollinger Bands indicate divergence between short-term and long-term trends.

As of 4 December 2025, the technical trend has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating bullish momentum. The weekly MACD is also mildly bullish, while the monthly MACD remains bearish, suggesting mixed signals across time frames. The RSI shows a bullish signal on the monthly chart, but no signal on the weekly, indicating potential strength in the longer term. Bollinger Bands are bullish on the weekly but mildly bearish on the monthly, adding to the mixed outlook. Overall, the strength of the bullish stance is moderate, with key indicators showing divergence between short-term and long-term trends.

How has been the historical performance of Orchid Pharma?

Orchid Pharma has shown significant financial improvement from March 2023 to March 2025, with net sales increasing from 665.90 Cr to 921.93 Cr, and consolidated net profit rising from 46.32 Cr to 99.66 Cr, indicating strong recovery and growth. Total assets and liabilities grew in tandem, while cash flow from operations improved markedly.

Answer:<BR>The historical performance of Orchid Pharma shows a significant improvement in financial metrics over the years, particularly from March 2023 to March 2025.<BR><BR>Breakdown:<BR>Orchid Pharma's net sales have steadily increased from 665.90 Cr in March 2023 to 921.93 Cr in March 2025, reflecting a robust growth trajectory. The total operating income followed a similar trend, rising from 665.90 Cr to 921.93 Cr during the same period. The company's operating profit (PBDIT) also improved significantly, increasing from 103.05 Cr in March 2023 to 144.65 Cr in March 2025, although the operating profit margin slightly decreased from 12.56% to 12.71%. Profit before tax rose from 55.25 Cr to 95.56 Cr, and profit after tax increased from 55.25 Cr to 95.76 Cr, indicating a strong recovery from previous losses. The consolidated net profit showed a remarkable increase from 46.32 Cr in March 2023 to 99.66 Cr in March 2025. On the balance sheet, total assets grew from 1,225.21 Cr to 1,687.91 Cr, while total liabilities increased from 1,225.21 Cr to 1,687.91 Cr, reflecting a balanced growth in both assets and liabilities. Cash flow from operating activities improved, with a net cash inflow of 17.00 Cr in March 2025 compared to a net outflow of 19.00 Cr in March 2024. Overall, Orchid Pharma's financial performance demonstrates a strong recovery and growth in key areas over the past few years.

Is Orchid Pharma overvalued or undervalued?

As of July 21, 2025, Orchid Pharma is considered overvalued with a PE ratio of 36.74 and an EV to EBITDA of 31.21, significantly higher than its peers, and has underperformed with a year-to-date return of -60.27% compared to the Sensex's gain of 5.20%.

As of 21 July 2025, Orchid Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its relative valuation. Despite this change, the company appears to be overvalued based on its current financial metrics. The PE ratio stands at 36.74, while the EV to EBITDA ratio is 31.21, both of which are significantly higher than many of its peers. Additionally, the PEG ratio of 4.17 suggests that the stock may be priced too high relative to its growth prospects.<BR><BR>In comparison to its peers, Sun Pharma has a PE of 35.52 and an EV to EBITDA of 25.11, while Cipla shows a more attractive valuation with a PE of 22.6 and an EV to EBITDA of 15.65. These comparisons highlight that Orchid Pharma's valuation is not justified when considering its earnings and growth potential. Furthermore, the company's year-to-date return of -60.27% starkly contrasts with the Sensex's gain of 5.20%, reinforcing the notion that Orchid Pharma is currently overvalued.

Who are the top shareholders of the Orchid Pharma?

The top shareholders of Orchid Pharma include Dhanuka Laboratories Limited with a 69.84% stake, mutual funds at 18.79% (led by Quant Small Cap Fund at 6.83%), Foreign Institutional Investors at 2.69%, and individual investors holding 5.11%. There are no pledged promoter holdings reported.

The top shareholders of Orchid Pharma include Dhanuka Laboratories Limited, which holds the highest promoter stake at 69.84%. Additionally, mutual funds collectively hold 18.79% of the shares, with the Quant Mutual Fund - Quant Small Cap Fund being the largest public shareholder at 6.83%. Foreign Institutional Investors (FIIs) have a stake of 2.69%, and individual investors hold 5.11% of the shares. There are no pledged promoter holdings reported.

Has Orchid Pharma declared dividend?

Orchid Pharma has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of September 13, 2012. However, the dividend yield is 0%, and total returns have shown significant volatility, with notable gains over the 5-year period despite recent declines.

Orchid Pharma Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3<BR>- Ex-date: 13 Sep 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -59.45%, the dividend return was 0%, resulting in a total return of -59.45%.<BR><BR>For the 1-year period, the price return was -32.95%, the dividend return was 0%, leading to a total return of -32.95%.<BR><BR>Over the 2-year period, the price return was 72.37%, with a dividend return of 0%, resulting in a total return of 72.37%.<BR><BR>In the 3-year period, the price return was 137.39%, the dividend return was 0%, culminating in a total return of 137.39%.<BR><BR>For the 4-year period, the price return was -49.4%, with a dividend return of 0%, leading to a total return of -49.4%.<BR><BR>In the 5-year period, the price return was 13462.86%, with a dividend return of 0%, resulting in a total return of 13462.86%.<BR><BR>Overall, while Orchid Pharma has declared a dividend, the dividend yield remains at 0%, indicating that the dividend has not contributed to returns in recent periods. The total returns show significant volatility, with substantial gains over longer periods, particularly in the 5-year timeframe.